Restructure Information
On September 15, 2019, Purdue announced a preliminary agreement to settle the massive opioid litigation facing the Company. To implement this settlement and secure a final resolution of all pending litigation, Purdue and its subsidiaries voluntarily filed petitions for reorganization under Chapter 11 of the U.S. Bankruptcy Code.
If you believe you have a claim against Purdue or any of its subsidiaries, please click “Read More Here” below for further information about the Proof of Claim process. JUNE 30, 2020 is the “Bar Date” – THE DEADLINE for every person or entity to submit a Proof of Claim.
Our Commitment to Safety as we Navigate Coronavirus
We have always been guided by our core values—Collaboration, Integrity, Courage, and Innovation—but now, facing the challenges posed by COVID-19, our core values have taken on new meaning. The health and safety of our colleagues, customers and community, along with the continuity of business operations – critical to serve patients who rely on our medicines and products – are our top priorities.
Our manufacturing facilities are open and operating but, where our workforce can work from home, they are doing so. We have taken special measures to protect those who continue to work on-site during this time, including enhanced cleaning, shift adjustments, social distancing, and business continuity planning, among other measures.
Our business remains open. Our products are available, and we have not identified any supply chain risks at this time. We continue to progress our public health initiatives and our pipeline. Please continue to contact us through your normal channels. Our medical team is available and if you have questions related to our products please contact us; 1-888-726-7535; www.AskPurdueMedical.com. Other contact information can be found here.
We are particularly concerned that the pandemic is triggering indirect health risks for people with (or those at risk of experiencing) substance use disorders. Through our office of Corporate Social Responsibility, Purdue is providing $500,000 in additional monetary support to local and national organizations focused on the pandemic, as well as those delivering harm reduction programs, improving access to medication-assisted treatment, and supporting continuity of recovery services during the pandemic.
We are confident that, by facing new challenges through a data-driven, health-conscious, and business continuity-focused lens,
we can continue to serve those who rely on our medicines and products.
Adlon Therapeutics L.P. is a biopharmaceutical company dedicated to developing and providing treatment options for ADHD and related disorders. Our initial focus is on adults and adolescents who suffer from symptoms of Attention Deficit/Hyperactivity Disorder (ADHD). Adlon is a subsidiary of Purdue Pharma L.P.
Adhansia XR™
(Methylphenidate Hydrochloride) Extended-Release Capsules CII
Warning: Abuse and Dependence
CNS stimulants, including Adhansia XR, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy.
